Sale rumors raise both Bausch + Lomb and Parent Bausch Health – Possible breakthrough

Edmund Ingham is a biotechnology consultant. He has been involved in biotechnology, healthcare and pharmaceuticals for over 5 years and has produced detailed reports on over 1,000 companies. He heads the Haggerston BioHealth investment group.

The group is designed for both beginner and experienced biotech investors. It provides catalysts to watch out for, as well as buy and sell ratings. It also provides product sales and forecasts for all Big Pharma, forecasting, integrated financial statements, discounted cash flow analysis, and market-by-market analysis. Learn more.

Analyst Disclosure: I/We do not own shares, options or similar derivative positions in any of the companies mentioned, but we can initiate a profitable long position by purchasing shares or purchasing a call option or similar derivatives in BLCO, BHC in the next 72 hours. This article was written by me and is my own opinion. I am not being compensated for it (outside of Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Quest for Alpha Revelation: Past performance is not a guarantee of future results. We do not provide any recommendation or advice as to whether a particular investment is suitable for a specific investor. Any views or opinions expressed above may not reflect the views of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker, or US investment advisor or investment bank. Our analysts are third-party authors, including both professional and individual investors, who may not be licensed or certified by any institute or regulatory body.